Minimally differentiated acute myeloid leukemia (AML MO): Clinico-biological findings of 29 cases

Twenty-nine cases of minimally differentiated acute myeloid leukemia or AML M0 identified among 441 AML diagnosed in the last 12 years are reported. I n all cases, flow cytometric analysis using a large panel of monoclonal ant ibodies and cytogenetic and molecular studies (IgH, TcR beta, BCR/ABL, AML1 /ETO and CBFB-MYH11 rearrangements) were performed. Of the 29 patients, 27 were treated with intensive chemotherapy based on GIMEMA protocols. We note d a greater incidence of older (over 60 years) and male patients (52% and 6 5%, respectively). CD33, CD13, CD7 and TdT were expressed in 79.3%, 82.7%, 58.6% and 42.8% of cases, respectively. Antigenic MPO was present in 17 of 22 cases (77.3%). Most cases expressed CD34 (93.1%), HLA-DR (93.1%), CD117 (80%) and CD45RA (87%). CD45RO and CD90 were consistently negative. In all cases, we observed an up-expression of bcl-2 and a down-expression of CD95 with an inverse trend between the two markers (r-5253; p 0.03). Karyotypic abnormalities were demonstrated in 53.6% of cases. Of these, 6 involved chr omosomes 5, 7 and 8, t(9;22), confirmed by the BCR/ABL transcript, was dete cted in one case. Rearrangements of the TcR beta and IgH chains were observ ed in 3 and 2 cases, respectively. No AML1/ETO and CBFB-MYH11 transcripts w ere found. Twelve out of 27 patients (44%) achieved a complete remission (C R) (in 2 cases after rescue therapy). Seven early (range 1-9 months) and on e late (32 months) relapses were observed. Five patients are alive, but onl y the 4 who underwent bone marrow transplantation are in persistent first C R. In conclusion, AML M0 is a subtype of AML antigenically well detectable, endowed with many adverse parameters (older age, TdT and CD34 expression, resistance to apoptosis, unfavorable cytogenetic abnormalities) and poor pr ognosis. A very aggressive consolidation treatment can be useful to improve the outcome.